WASHINGTON — In one of his last moves before retirement, Sen. Orrin Hatch (R-Utah) slammed one of the Trump administration’s splashiest drug pricing plans and called for his colleagues to limit the power of the Trump administration to pursue the proposal.
Until now, Hatch has largely refrained from openly criticizing the Trump administration’s drug pricing plans, even as some have broken with Republican orthodoxy. Wednesday’s letter is perhaps the clearest sign to date of tensions emerging in the Republican party over the administration’s’ drug pricing policies.
“While the Administration is pursuing many positive proposals, I am compelled to speak out against policies that run counter to our principles,” Hatch writes in a letter to his colleagues dated Dec. 19, which was obtained by STAT.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect